Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/− cetuximab in oesophageal cancer

BACKGROUND: The SCOPE-1 study tested the role of adding cetuximab to conventional definitive chemoradiotherapy (dCRT), and demonstrated greater toxicity and worse survival outcomes. We present the long-term outcomes and patterns of recurrence. METHODS: SCOPE-1 was a phase II/III trial in which patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Crosby, T, Hurt, C N, Falk, S, Gollins, S, Staffurth, J, Ray, R, Bridgewater, J A, Geh, J I, Cunningham, D, Blazeby, J, Roy, R, Maughan, T, Griffiths, G, Mukherjee, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355926/
https://www.ncbi.nlm.nih.gov/pubmed/28196063
http://dx.doi.org/10.1038/bjc.2017.21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355926/
https://www.ncbi.nlm.nih.gov/pubmed/28196063
http://dx.doi.org/10.1038/bjc.2017.21

Ejemplares similares